{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-033616","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.228613+00:00","generated_at":"2026-05-16T23:49:47.222736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eton Q3 product sales $22.5M (+129% YoY), non-GAAP EPS $0.04, ET-600 PDUFA Feb 2026","bullets":["Product sales of $22.5M, up 129% YoY; 19th consecutive quarter of sequential growth.","GAAP EPS loss $0.07; non-GAAP diluted EPS $0.04; Adjusted EBITDA $2.9M.","ET-600 NDA accepted with PDUFA date February 25, 2026; launch production scheduled.","INCRELEX largest revenue contributor; GALZIN exceeded year-end target of 200 active patients.","Generated $12.0M cash from operations; ending cash balance $37.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-033616","json":"https://secwatch.observer/filing/0001437749-25-033616.json","markdown":"https://secwatch.observer/filing/0001437749-25-033616.md","text":"https://secwatch.observer/filing/0001437749-25-033616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/0001437749-25-033616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/eton20250819_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:49:47.222736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}